Sidera Bio

Sidera Bio is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, founded in 2023 and focused on developing transformative therapies for serious cardiometabolic diseases. The company specializes in first-in-class triple agonist therapeutics that simultaneously activate GLP-1, GIP, and FGF21 receptor pathways, designed to ad... dress metabolic dysfunction, obesity, type 2 diabetes, nonalcoholic steatohepatitis, and related cardiometabolic conditions. Sidera Bio has secured exclusive global rights outside Greater China to develop and commercialize MWN105, a novel unimolecular GLP-1/GIP/FGF21 triple agonist licensed from Beijing-based Lepu Medical Technology, which is engineered to regulate appetite, glucose metabolism, and lipid balance simultaneously with potentially superior efficacy compared to single or dual agonist drugs. The company raised 109 million dollars in Series A financing in December 2025, led by prominent life sciences investors including Novo Holdings and Forbion, with additional backing from RA Capital and others. As part of the licensing agreement with Lepu Medical, Sidera Bio received a 9.99 percent equity stake from Lepu and structured milestone payments of up to 1.01 billion dollars plus future royalties. The company employs a genetic research platform that uses human genetics to study disease mechanisms and identify genes associated with disease susceptibility and protection, enabling the development of personalized medicine approaches. Sidera Bio is positioned to enter first-in-human clinical studies in Europe in 2026, competing in the rapidly evolving next-generation metabolic therapeutics market alongside other multi-agonist candidates targeting obesity and cardiometabolic disease.Read More